Custom service

Drug-Tolerant ADA Assays

Detect ada in samples with high circulating drug levels

Turnaround: 8–12 weeksTypical scale: µg – g sample scaleChemistry options: acid dissociation and bead-based pretreatment; drug-tolerant bridging formats; drug-interference characterization

Drug-Tolerant ADA Assays supports programmes that detect ADA in samples with high circulating drug levels. In a typical engagement we plan the acid dissociation and bead-based pretreatment route first, confirm compatibility with drug-tolerant bridging formats, and release drug-tolerant assay with validation data on a 8–12 weeks schedule.

Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep acid dissociation and bead-based pretreatment as the primary option and hold drug-tolerant bridging formats in reserve, so that scale-up never depends on an unproven step.

High-dose biologics where standard ADA fails

Re-dosing programs after immunogenicity signals

Products with manageable drug interference

Samples requiring containment or licensing we do not hold (BSL-3, radioactive)

Analytical reports follow a fixed template: sample condition on receipt, method description with validation status, raw chromatograms and spectra, results with uncertainty, and an interpretation note. Urgent same-week slots are available for release-critical testing.

Service Highlights

  • Acid dissociation and bead-based pretreatment as the default route, with drug-tolerant bridging formats held as a proven fallback
  • Drug-interference characterization worked into the design where the application requires it
  • Results are reported with detection limits and method validation status, so you know exactly what the number means
  • Analytical confirmation of every intermediate before the final release
  • Orthogonal methods are used by default — one measurement is an observation, two are data
  • Drug-tolerant assay with validation data delivered with a complete conjugation or synthesis certificate

How the work runs

  1. Sample intake & plan

    Samples are logged with chain of custody and the test matrix for Drug-Tolerant ADA Assays is confirmed.

  2. Method selection

    Analytical methods — acid dissociation and bead-based pretreatment, drug-tolerant bridging formats — are chosen and their validation status documented.

  3. Measurement

    Testing is executed with system-suitability checks and orthogonal confirmation where required.

  4. Data review

    Chromatograms and spectra are reviewed by a second analyst before any result is issued.

  5. Reporting

    Drug-tolerant assay with validation data is issued with detection limits and interpretation notes.

  6. Follow-up support

    We discuss anomalies and, where useful, propose the follow-up experiment that resolves them.

Specifications & timeline

Turnaround
8–12 weeks
Typical scale
µg – g sample scale
Chemistry options
acid dissociation and bead-based pretreatment; drug-tolerant bridging formats; drug-interference characterization
Deliverable
Drug-tolerant assay with validation data
QC package
Method report, raw data, validated result with detection limits
Shipping
Blue ice or ambient by material; chain-of-custody on receipt

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.